Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials

被引:26
作者
Chen, Yu-Pei [1 ]
Sun, Ying [1 ]
Chen, Lei [1 ]
Mao, Yan-Ping [1 ]
Tang, Ling-Long [1 ]
Li, Wen-Fei [1 ]
Liu, Xu [1 ]
Zhang, Wen-Na [1 ]
Zhou, Guan-Qun [1 ]
Guo, Rui [1 ]
Lin, Ai-Hua [2 ]
Ma, Jun [1 ]
机构
[1] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Dept Radiat Oncol, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou 510060, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Nasopharyngeal carcinoma; Surrogate endpoint; Chemotherapy; Radiotherapy; Failure-free survival; Progression-free survival; COMPARING NEOADJUVANT CHEMOTHERAPY; CONCURRENT CISPLATIN-RADIOTHERAPY; PLUS ADJUVANT CHEMOTHERAPY; PROGRESSION-FREE SURVIVAL; LONG-TERM SURVIVAL; PHASE-III; INDUCTION CHEMOTHERAPY; WEEKLY OXALIPLATIN; THERAPEUTIC GAIN; ENDEMIC REGIONS;
D O I
10.1016/j.radonc.2015.07.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: We used a literature-based meta-analysis to assess whether failure-free survival (FFS) or progression-free survival (PFS) could be reliable surrogate endpoints for overall survival (OS) in trials of combined chemotherapy and radiotherapy for nasopharyngeal carcinoma (NPC). Methods and materials: We identified randomised trials that evaluated combined chemoradiotherapy strategies, and reported FFS or PFS and OS in NPC. We analysed the treatment effects on FFS or PFS, and OS. We used the coefficient of determination (R-2), and the surrogate threshold effect (STE) to assess the trial-level correlation. Results: Twenty-one trials (5212 patients), with sixteen treatment-control comparisons for FFS, and nine for PFS, were analysed. FFS was strongly correlated with OS (R-2 = 0.88, STE = 0.84), as was PFS (R-2 = 0.90, STE = 0.88). Moreover, FFS and PFS at 3 years were still strongly correlated with 5-year OS (R-2 = 0.80, STE = 0.83; R-2 = 0.85, STE = 0.84). Conclusions: Both FFS and PFS could be valid surrogate endpoints for OS in trials of combined chemotherapy and radiotherapy for NPC; PFS may be a more acceptable surrogate endpoint compared with FFS. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:157 / 166
页数:10
相关论文
共 51 条
[1]   DOES CHEMOTHERAPY IMPROVE SURVIVAL IN ADVANCED BREAST-CANCER - A STATISTICAL OVERVIEW [J].
AHERN, RP ;
EBBS, SR ;
BAUM, MB .
BRITISH JOURNAL OF CANCER, 1988, 57 (06) :615-618
[2]   Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099 [J].
Al-Sarraf, M ;
LeBlanc, M ;
Giri, PGS ;
Fu, KK ;
Cooper, J ;
Vuong, T ;
Forastiere, AA ;
Adams, G ;
Sakr, WA ;
Schuller, DE ;
Ensley, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1310-1317
[3]   Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients [J].
Baujat, B ;
Audry, W ;
Bourhis, J ;
Chan, ATC ;
Onat, H ;
Chua, DTT ;
Kwong, DLW ;
al-Sarraf, M ;
Chi, KH ;
Hareyama, M ;
Leung, SF ;
Thephamongkhol, K ;
Pignon, JP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (01) :47-56
[4]   Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients [J].
Blanchard, Pierre ;
Lee, Anne W. M. ;
Leclercq, Julie ;
Marguet, Sophie ;
Ng, Wai Tong ;
Ma, Jun ;
Chan, Anthony T. C. ;
Huang, Peiyu ;
Zhu, Guopei ;
Chua, Daniel T. T. ;
Mai, Hai Qiang ;
Wee, Joseph ;
Kwong, Dora L. W. ;
Moon, James ;
Chi, Kwan Hwa ;
Fountzilas, George ;
Hareyama, Masuto ;
Zhang, Li ;
Bourhis, Jean ;
Pignon, Jean-Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[5]   Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer [J].
Burzykowski, Tomasz ;
Buyse, Marc ;
Piccart-Gebhart, Martine J. ;
Sledge, George ;
Carmichael, James ;
Lueck, Hans-Joachim ;
Mackey, John R. ;
Nabholtz, Jean-Marc ;
Paridaens, Robert ;
Biganzoli, Laura ;
Jassem, Jacek ;
Bontenbal, Marijke ;
Bonneterre, Jacques ;
Chan, Stephen ;
Basaran, Gul Atalay ;
Therasse, Patrick .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :1987-1992
[6]   Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation [J].
Burzykowski, Tomasz ;
Buyse, Marc .
PHARMACEUTICAL STATISTICS, 2006, 5 (03) :173-186
[7]  
Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49
[8]   Individual- and trial-level surrogacy in colorectal cancer [J].
Buyse, Marc ;
Burzykowski, Tomasz ;
Michiels, Stefan ;
Carroll, Kevin .
STATISTICAL METHODS IN MEDICAL RESEARCH, 2008, 17 (05) :467-475
[9]   Current treatment of nasopharyngeal carcinoma [J].
Chan, Anthony T. C. .
EUROPEAN JOURNAL OF CANCER, 2011, 47 :S302-S303
[10]   Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma [J].
Chan, ATC ;
Leung, SF ;
Ngan, RKC ;
Teo, PML ;
Lau, WH ;
Kwan, WH ;
Hui, EP ;
Yiu, HY ;
Yeo, W ;
Cheung, FY ;
Yu, KH ;
Chiu, KW ;
Chan, DT ;
Mok, TSK ;
Yau, S ;
Yuen, KT ;
Mo, FKF ;
Lai, MMP ;
Ma, BBY ;
Kam, MKM ;
Leung, TWT ;
Johnson, PJ ;
Choi, PHK ;
Zee, BCY .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (07) :536-539